FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | UI Secti | 011 30(1 | 1) 0 | ii iiie iii | vesun | ent co | πραπ | ACI UI | 1940 | | | | | | | |
|--|---|------------------------------------|---|---|---|--|--|----------------|---|---------------|---|--|--|---|--|---------------|--|---|--|
| 1. Name and Address of Reporting Person* <u>EW Healthcare Partners, L.P.</u> | | | | 2. Issuer Name and Ticker or Trading Symbol EyePoint Pharmaceuticals, Inc. [EYPT] | | | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner | | | | | |
| (Last) (First) (Middle) 21 WATERWAY AVENUE, SUITE 225 | | | | 3. Date of Earliest Transaction (Month/Day/Year) 08/24/2023 | | | | | | | | | Officer (give title X Other (specify below) See footnotes 1 and 6 | | | | | | |
| | | | | 4. If Am | endme | nt, | Date of | f Origin | nal File | d (Mor | nth/Day | Year) |) 6. | . Individual o | r Joint/ | Group Fili | ng (Cl | heck Ap | plicable |
| (Street) | | | | 08/28/2 | 2023 | | | | | , | | , | Li | ine) Form | ı filed b | y One Re | portin | a Perso | on I |
| THE WOODLANDS TX 77 | | 7380 | | | | | | | | | | X Form filed by More than One Reporting Person | | | | | | | |
| (City) (State) (Zip | | | Zip) | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to | | | | | | | | | | | | | | | |
| | | | | sati | sfy the a | affiri | mative d | lefense | conditi | ons of I | Rule 10h |)5-1(c) |). See Instr | ruction 10. | | or written pl | an tha | t is inter | ded to |
| | | | I - Non-Deriva | | | es | | uirec | _ | | | | | | | | | | |
| 1. Title of Security (Instr. 3) | | | 2. Transaction Date (Month/Day/Year) | Execution if any | 2A. Deemed Execution Date, if any (Month/Day/Yea | | Code (II | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5 | | | or 4 and 5) | 5. Amount Securities Beneficially Owned Following | | Form: Di (D) or | Indirect (I) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | Code | v | Amou | ınt | (A) or (D) | Pric | e | Reported Transaction (Instr. 3 and | | , , | | | | |
| Common Stock, \$0.001 par value | | | 08/24/2023 | | | | S | | 87, | 87,100 | | \$11.54(2)(7) | | 3,935,940 | | | | See Footnotes ⁽¹⁾⁽⁶⁾ | |
| Common Stock, \$0.001 par value | | | 08/24/2023 | | | | S | | 52,180 | | D | \$10.56 ⁽³⁾⁽⁷⁾ | | 3,883,760 | | | | See Footnotes ⁽¹⁾⁽⁶⁾ | |
| Common Stock, \$0.001 par value | | | 08/25/2023 | | | | S | | 72,925 | | D | \$11.09(4)(7) | | 3,810,835 | | I | | See Footnotes ⁽¹⁾⁽⁶⁾ | |
| Common Stock, \$0.001 par value | | | 08/25/2023 | | | | S | | 11,731 | | D | \$10.45(5)(7) | | 3,799,104 | | I | | See Footnotes ⁽¹⁾⁽⁶⁾ | |
| | | Tal | ble II - Derivat (e.g., pu | ive Secu Its, call | uritie s, wa | s A | Acqui ants, | ired, optic | Disp ons, o | osed conv | of, o | r Be | neficia curities | lly Owne s) | d | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | | 3A. Deemed Execution Date, if any (Month/Day/Year) | Transaction of Code (Instr. 8) Se Ac (A) Dis of (In | | f eriv ecu cqu ispo ispo f (D) | rivative curities quired or sposed | | te Exercisable an ration Date th/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Inst | | int of rities rlying ative rity (Instr. | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code V | (A | N) | | Date Exerc | isable | Expir Date | | Title | Amount or Number of Shares | | | | | | |
| | | f Reporting Person* Partners, L.P. | | | | | | | | | | | | | | | | | |
| (Last) 21 WAT | ERWAY A | (First) VENUE, SUITE | (Middle) 225 | | | | | | | | | | | | | | | | |
| (Street) THE WOODI | LANDS | TX | 77380 | | | | | | | | | | | | | | | | |
| (City) | | (State) | (Zip) | | | | | | | | | | | | | | | | |
| | | f Reporting Person* Partners-A, L | | | | | | | | | | | | | | | | | |
| - | | | | | 1 | | | | | | | | | | | | | | |

(Middle)

(First) 21 WATERWAY AVENUE, SUITE 225

(Street)

| THE WOODLANDS | TX | 77380 | | | | | |
|---|--|-------|--|--|--|--|--|
| (City) | (State) | (Zip) | | | | | |
| | Name and Address of Reporting Person* <u>SSEX Woodlands Fund IX-GP, L.P.</u> | | | | | | |
| (Last) 21 WATERWAY A | (Last) (First) (Middle) 21 WATERWAY AVENUE, SUITE 225 | | | | | | |
| (Street) THE WOODLANDS | TX | 77380 | | | | | |
| (City) | (State) | (Zip) | | | | | |
| Name and Address of Reporting Person* Essex Woodlands IX, LLC | | | | | | | |
| (Last) 21 WATERWAY A | (Last) (First) (Middle) 21 WATERWAY AVENUE, SUITE 225 | | | | | | |
| (Street) THE WOODLANDS | TX | 77380 | | | | | |
| (City) | (State) | (Zip) | | | | | |

Explanation of Responses:

- 1. The share totals shown above are the aggregate amounts of shares of Common Stock sold by EW Healthcare Partners, L.P. ("EWHP") and EW Healthcare Partners-A, L.P. ("EWHP-A") on the dates set forth above. EWHP sold 133,890 shares and 81,380 shares of the amounts shown above on August 24, 2023 and August 25, 2023, respectively, and EWHP-A sold 5,390 shares and 3,276 shares of the amounts shown above on August 24, 2023 and August 25, 2023, respectively. EWHP now holds a total of 3,652,177 shares of Common Stock of the Issuer and EWHP-A now holds a total of 146,927 shares of Common Stock of the Issuer.
- 2. Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from \$11.05 to \$12.04. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 3. Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from \$10.11 to \$11.04. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 4. Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from \$10.5001 to \$11.50. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 5. Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date within a one dollar range. Actual prices ranged from \$10.36 to \$10.50. The Reporting Persons hereby undertake to provide upon request of the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 6. Essex Woodlands Fund IX-GP, L.P. (the "EW Fund IX GP"), is the general partner of each of EW Healthcare Partners, L.P. ("EWHP") and EW Healthcare Partners-A, L.P. ("EWHP-A" and together with EWHP, the "EWHP Funds"). Essex Woodlands IX, LLC (the "General Partner") is the general partner of EW Fund IX GP. The General Partner holds sole voting and dispositive power over the shares held by each of the EW Funds (the "Shares"). The managers of the General Partner are Martin P. Sutter, Scott Barry, Ron Eastman, Petri Vainio and Steve Wiggins (collectively, the "Managers") and may exercise voting and investment control over the Shares only by majority action of the Managers. Each individual Manager, the EW Funds GP and the General Partner disclaims ownership over the Shares except to the extent of his or its respective pecuniary interest therein.
- 7. This Amended Form 4 is being filed to correct an administrative error in reporting the weighted average prices at which shares were sold on August 24, 2023 and August 25, 2023 from that reported in the original Form 4 to the prices shown in this Amended Form 4.

Remarks:

EW Healthcare Partners, L.P.; By Essex Woodlands Fund IX-GP, L.P., its General Partner; By Essex Woodlands 08/30/2023 IX, LLC, its General Partner; By Ronald Eastman, Manager; By Gregory L. Hill, Attorneyin-Fact, /s/Gregory L. Hill EW Healthcare Partners-A, L.P.; By Essex Woodlands Fund IX-GP, L.P., its General Partner; By Essex Woodlands 08/30/2023 IX, LLC, its General Partner; By Ronald Eastman, Manager; By Gregory L. Hill, Attorneyin-Fact, /s/ Gregory L. Hill Essex Woodlands Fund IX-GP, L.P.; By Essex Woodlands IX, LLC, its General Partner; 08/30/2023 By Ronald Eastman, Manager; By Gregory L. Hill, Attorneyin-Fact, /s/ Gregory L. Hill Essex Woodlands IX, LLC; By Ronald Eastman, Manager; 08/30/2023 By Gregory L. Hill, Attorneyin-Fact, /s/ Gregory L. Hill ** Signature of Reporting Person

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.